Clinical trials: Hot Flashes
Hot Flashes, Breast Cancer
Evaluate RCN3028 in Treatment of Drug-Induced VMS in Breast Cancer
Due to the fact that majority of breast cancers are estrogen-receptor and/or progesterone receptor positive, tamoxifen and aromatase inhibitors (AIs) are among the mainstay therapies to treat breast cancer.
- Trial name
- VMS (NCT06161792)
- Testing
- 0.8 mg RCN3028
- Where
- 4 sites in Taiwan
- Volunteers
- 10 people
- Sponsor
- Yung Shin Pharm. Ind. Co., Ltd.
Postmenopausal Symptoms
A Study of the Safety and Effect of Repeated Administration of G-CSF on Hot Flashes in Postmenopausal Women
The purpose of this study is to assess the efficacy and safety of repeated administration of G-CSF for the treatment of hot flashes and vasomotor symptoms in women with naturally-occurring or surgically induced menopause.
- Trial name
- NCT03640754
- Testing
- G-CSF
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- MenoGeniX, Inc.
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes
A Study to Learn How Safe the Study Treatment Elinzanetant is and How it Moves Into, Through and Out of the Body When Given as Single Increasing Doses That Are Higher Than Normally Used Compared to Placebo and Moxifloxacin in Healthy Participants
Researchers are looking for a better way to treat vasomotor symptoms, a condition of having hot flashes. The condition is caused by hormonal changes and occurs primarily in women, but can also affect men.
- Conditions
- Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes, Healthy Volunteers
- Trial name
- NCT05481528
- Testing
- Moxifloxacin, Elinzanetant (BAY3427080)
- Where
- Germany
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Bayer
Menopause, Hot Flashes
A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms
The purpose of this study is to determine the effectiveness of BAY3427080 (NT-814), taken once a day, in the treatment of troublesome post-menopausal symptoms.
- Conditions
- Menopause, Hot Flashes, Night Waking
- Trial name
- SWITCH-1 (NCT03596762)
- Testing
- Elinzanetant (BAY3427080)
- Where
- 25 sites in United States, Canada and 1 more
- Volunteers
- 199 people
- Sponsor
- Bayer
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes
A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants
Researchers are looking for a better way to treat men and women with vasomotor symptoms, a condition of having hot flashes caused by hormonal changes.
- Conditions
- Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes, Healthy Volunteers
- Trial name
- NCT05471817
- Testing
- Elinzanetant (BAY3427080), Dabigatran etexilate
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bayer
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes
A Study to Learn More About How the Study Treatment Elinzanetant (or BAY3427080) Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body After Taking Single and Multiple Doses in Healthy Women Aged 40 to 65 Years
Researchers are looking for a better way to treat men and women with vasomotor symptoms, a condition of having hot flashes caused by hormonal changes.
- Conditions
- Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes, Healthy Volunteers
- Trial name
- NCT05381142
- Testing
- Elinzanetant (BAY3427080)
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bayer
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes
A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants
Researchers are looking for a better way to treat men and women with vasomotor symptoms, a condition of having hot flashes caused by hormonal changes.
- Conditions
- Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes, Healthy Volunteers
- Trial name
- NCT05351892
- Testing
- Elinzanetant (BAY3427080)
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bayer
Prostate Cancer, Hot Flashes
Embr Thermal Device for Hot Flash Management in Prostate Cancer
This study is being conducted to evaluate if the Embr thermal device is useful for men who experience bothersome hot flashes as a result of prostate cancer treatment.
- Trial name
- NCT04892914
- Testing
- Embr thermal device
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Embr Labs, Inc.
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes
A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults
Researchers are looking for a better way to treat people who have vasomotor symptoms (VMS). VMS such as hot flashes are caused by hormonal changes occurring during menopausal transition when women may have also changes in their…
- Trial name
- NCT05061563
- Testing
- Elinzanetant (BAY3427080), Esomeprazole
- Where
- Netherlands
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bayer
PMS, Hot Flashes
A Study to Evaluate the Effects of RCN3028 on Moderate to Severe Vasomotor Symptoms in Women
Hot flashes are the most common symptom of menopause and affect almost 75% of menopausal women. Clinical evidence indicates potent antagonists of 5-HT2A are more likely to cause hypothermia.
- Trial name
- RDC (NCT02100540)
- Testing
- II RDC 0.3mg capsule, III RDC 0.6mg capsule
- Where
- Taiwan
- Volunteers
- 58 people
- Sponsor
- Yung Shin Pharm. Ind. Co., Ltd.
Hot Flashes
Phase 2 Study of SJX-653 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms
This study evaluates the efficacy, safety, tolerability, and pharmacokinetics of once daily SJX-653 in postmenopausal women with moderate to severe VMS.
- Trial name
- NCT04278872
- Testing
- SJX-653
- Where
- 22 sites in Belgium, Germany and 2 more
- Volunteers
- 13 people
- Sponsor
- Sojournix, Inc.
Menopause, Dietary Supplements
Effects of a New Botanical Extracts Combination on Quality of Life in Menopausal Spanish Women
This study was designed to evaluate the beneficial effects and safety of a standardised botanical extract combination containing soy isoflavone extract, grains of paradise seed dry extract and pomegranate skin dry extract on…
- Conditions
- Menopause, Dietary Supplements, Quality of Life
- Trial name
- NCT04381026
- Testing
- Botanical dry extracts combination
- Where
- Spain
- Volunteers
- 57 people
- Sponsor
- Nektium Pharma SL
Hot Flashes
Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women
Depomed's Gabapentin Extended Release is an investigational, extended release formulation of Gabapentin that is being studied for the treatment of Hot Flashes/Hot Flushes in postmenopausal women
- Trial name
- Breeze3 (NCT01080300)
- Testing
- Gabapentin Extended Release
- Where
- 66 sites in United States
- Volunteers
- 600 people
- Sponsor
- Depomed
Vasomotor Symptoms (VMS)
Dose Escalation Study in Female Subjects With Breast Cancer Receiving Aromatase Inhibitor or Tamoxifen
Open-label, two dose study of Q-122, over a 4 week treatment period to explore the effects of Q-122 in a population of women with a history of breast cancer taking an aromatase inhibitor or tamoxifen.
- Trial name
- NCT04080297
- Testing
- oral capsule of Q-122
- Volunteers
- 21 people
- Sponsor
- Que Oncology
Menopause
A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms
This study will be a prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter trial of postmenopausal subjects with an intact uterus.
- Trial name
- REPLENISH (NCT01942668)
- Testing
- Estradiol, Progesterone
- Where
- 119 sites in United States
- Volunteers
- 1,845 people
- Sponsor
- TherapeuticsMD
Vasomotor Symptoms, Hot Flashes
Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms
The primary objective of this study was to determine the clinical safety of RAD1901 and to evaluate whether RAD1901 reduced the frequency and severity of moderate to severe vasomotor symptoms (VMS; "hot flashes") in…
- Trial name
- NCT02653417
- Testing
- RAD1901
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- Radius Pharmaceuticals, Inc.
Vasomotor Symptoms; Hot Flashes
Study of Erenumab (AMG 334) in Women With Hot Flashes
The primary objective of this study was to evaluate the frequency of moderate to severe daily hot flashes 4 weeks after a single dose of erenumab (AMG 334) in women with hot flashes associated with menopause.
- Trial name
- NCT01890109
- Testing
- Erenumab
- Where
- 7 sites in United States
- Volunteers
- 103 people
- Sponsor
- Amgen
Menopausal Symptoms
A Clinical Trial on the Efficacy of a Combination Herbal Product, Biotropics' Nu Femme, on Menopausal Symptoms and Quality of Life in Women
The purpose of this study is to assess the effectiveness of an herbal combination product called Nu Femme, on menopausal symptoms in peri-menopausal women.
- Trial name
- 14NMHB (NCT02269891)
- Testing
- Nu Femme
- Where
- 4 sites in Canada
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- KGK Science Inc.
Hot Flashes
FP-101 for the Treatment of Hot Flashes in Postmenopausal Women
The purpose of the study is to determine the efficacy of FP-101 versus placebo for the treatment of hot flashes in postmenopausal women.
- Trial name
- NCT03285672
- Testing
- FP-101
- Where
- 12 sites in United States
- Volunteers
- 109 people
- Sponsor
- Fervent Pharmaceuticals
Hot Flashes
A Study to Evaluate the Effects of RAD1901 in the Treatment of Vasomotor Symptoms in Postmenopausal Women
The purpose of this study is to determine whether RAD1901 is effective in decreasing hot flashes in postmenopausal women.
- Trial name
- NCT00875420
- Testing
- RAD1901
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Radius Pharmaceuticals, Inc.